MetaCap

Alector (ALEC) vs Candel Therapeutics (CADL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alector (ALEC) has outperformed Candel Therapeutics (CADL) over the past year, gaining 88.3% versus a gain of 10.8%. Over five years, CADL leads with a -48.5% price change compared with -88.3% for ALEC. Candel Therapeutics is the larger company by market cap ($395.4 million vs $347.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALEC+88.31%CADL+10.77%
+213%+97%-19%
Nov 21, 20251 yearNov 20, 2026
ALEC-89.08%CADL-53.63%
+27%-37%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALEC versus CADL key metrics
MetricALECCADL
Share price$2.34$5.04
Market cap$347.63M$395.37M
1-day change+1.52%-1.75%
YTD return+49.68%-10.80%
1-year return+88.31%+10.77%
5-year return-88.28%-48.47%
P/E ratio (TTM)6.31—
EPS (TTM)$0.37$-1.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$21.05M—
Revenue growth (YoY)-79.07%—
Net income (latest FY)$-142.93M$-38.18M
Operating margin-741.30%—
Net margin-679.16%—
52-week high$2.84$14.00
52-week low$1.09$4.35
Distance from 52-week high-17.78%-64.00%
Analyst consensusbuystrong_buy
Avg. price target upside+89.29%+250.60%
Average volume3.34M1.26M
Shares outstanding148.88M78.45M
Employees10355
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALEC has outperformed CADL by 77.5 percentage points over the past year.

About Alector

ALEC stock →

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees

About Candel Therapeutics

CADL stock →

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees

ALEC vs CADL FAQ

Which is bigger, Alector or Candel Therapeutics?

Candel Therapeutics (CADL) is larger, with a market capitalization of $395.37M compared with $347.63M for Alector (ALEC).

Which stock has performed better over the past year, ALEC or CADL?

ALEC returned +88.31% over the past 12 months, compared with +10.77% for CADL (price return, excluding dividends). Past performance does not predict future results.

Are Alector and Candel Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons